EUVIMEDEUVIMED entdecken
Fallbericht

Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma

Işılay Taşkaldıran, Püren Gökbulut, Hasan Yiğit, Çağatay Emir Önder

Acta Diabetologica · 22.05.2026 · 63 (8) · 1339-1342

DOI: 10.1007/s00592-026-02702-8 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Acta Diabetologica, online erschienen am 22.05.2026. Verfasst von Işılay Taşkaldıran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Ankara Training and Research Hospital, University of Health Sciences, Ankara, Turkey. dr.isilaymenekse@ho…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Glucagon-Like Peptides, Adenocarcinoma, Blood Glucose. Die Arbeit nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists are widely used for the management of obesity and dysglycaemia, and current evidence does not support a causal association with pancreatic cancer. We report a 55-year old woman with obesity and prediabetes who started once-weekly semaglutide 0.25 mg for weight management and glycaemic control. Baseline fasting plasma glucose was 107 mg/dL and glycated haemoglobin was 6.0%. After one month, despite a 4 kg weight loss and no significant gastrointestinal symptoms, fasting plasma glucose increased to 169 mg/dL and glycated haemoglobin to 6.6%. Latent autoimmune diabetes in adults was excluded by negative autoantibodies and preserved C-peptide. Further evaluation revealed markedly elevated carbohydrate antigen 19-9 and pancreatic magnetic resonance imaging demonstrated a 4 × 3 cm irregular mass in the pancreatic head. Surgical exploration identified liver metastases, and biopsy confirmed metastatic pancreatobiliary adenocarcinoma. This case highlights that atypical glycaemic changes during early semaglutide treatment should be interpreted cautiously, particularly during subtherapeutic dose escalation. Such observations do not imply causality, but may warrant individualized assessment when accompanied by additional clinical suspicion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsGlucagon-Like PeptidesAdenocarcinomaBlood GlucoseHypoglycemic AgentsHumansSemaglutideFemaleMiddle AgedGlycated HemoglobinObesity

Stichwörter der Autor:innen

CA 19 − 9GLP-1 receptor agonistsGlycaemic changesPancreatic adenocarcinomaSemaglutide

Substanzen

SemaglutideGlucagon-Like PeptidesBlood GlucoseHypoglycemic AgentsGlycated Hemoglobin

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Ankara Training and Research Hospital, University of Health Sciences, Ankara, Turkey. dr.isilaymenekse@hotmail.com.
  • Department of Endocrinology and Metabolism, Ankara Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Department of Radiology, Ankara Training and Research Hospital, University of Health Sciences, Ankara, Turkey.

Zitieren

APA

Taşkaldıran, I., Gökbulut, P., Yiğit, H., & Önder, Ç. E. (2026). Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma. Acta Diabetologica, 63(8), 1339-1342. https://doi.org/10.1007/s00592-026-02702-8

Vancouver

Taşkaldıran I, Gökbulut P, Yiğit H, Önder ÇE. Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma. Acta Diabetologica. 2026;63(8):1339-1342. doi:10.1007/s00592-026-02702-8

BibTeX
@article{Takaldran2026,
  author = {Taşkaldıran, Işılay and Gökbulut, Püren and Yiğit, Hasan and Önder, Çağatay Emir},
  title = {Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma},
  journal = {Acta Diabetologica},
  year = {2026},
  volume = {63},
  number = {8},
  pages = {1339--1342},
  doi = {10.1007/s00592-026-02702-8}
}
Kostenlos starten →